Peptide YY: Obesity's cause and cure?

American Journal of Physiology - Endocrinology and Metabolism

Volumn 293, Issue 5, 2007, Pages

  Tschöp, Matthias H ^a   Ravussin, Eric ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; PEPTIDE FRAGMENT; PEPTIDE YY; PEPTIDE YY[3-36]; PROOPIOMELANOCORTIN; RIMONABANT; UNCLASSIFIED DRUG;

BODY FAT; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ENERGY BALANCE; FOOD AND DRUG ADMINISTRATION; FOOD INTAKE; HORMONE ACTION; HUMAN; LIPOLYSIS; LOW CALORY DIET; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SATIETY; TASTE AVERSION;

ANIMALS; ANTI-OBESITY AGENTS; EATING; HUMANS; MALE; MICE; OBESITY; PEPTIDE YY;

EID: 36148967306     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00568.2007     Document Type: Editorial

References (28)

1. Allison DB, Arndt K, Beattie AH, Beck-Sickinger AG, Benoit SC, Birringer M, Blundell JE, Boggiano MM, Castaneda TR, Chandler PC, Culler M, Datta R, Deng XY, Dong J, Halem H, Holch P, Ishii Y, Joost HG, Klaus S, Koglin N, Kreuzer OJ, Madsen K, Mark M, Ortmann S, Oswald KD, Raun K, Rodgers RJ, Rudolf K, Schindler M, Schoelch C, Seeley RJ, Stidsen CE, Taylor J, Thone-Reineke Tschop M CBS, Whitcomb DC, Wulff BS. PYY3-36 as an anti-obesity drug target. Obes Rev 6: 307-22, 2005.
2. Allison DB, Arndt K, Beattie AH, Beck-sickinger AG, Benoit SC, Birringer M, Blundell JE, Castaneda TR, Chandler PC, Craney S, Culler M, Datta R, Deng XY, Dong J, Flora D, Hagan MM, Halem H, Heiman ML, Holch P, Ishii 'Y, Joost HG, Kinzig KP, Klaus S, Koglin N, Kreuzer OJ, Madsen K, Mark M, Moran TH, Ortmann S, Oswald KD, Raun K, Rodgers RJ, Rudolf K, Schindler M, Seeley RJ, Smiley D, Stidsen CE, Taylor J, Thone-Reineke C, Tschop M, Whitcomb DC, Wulff BS. Physiology: does gut hormone PYY3-36 decrease food intake in rodents? Nature 430: 165-166, 2004.
3. Amatruda JM, Erondu N, Gantz I, Heymsfield SB, Krishna R, Macneil DJ, Mallick M, Musser B, Snyder K, Stevens C, Stroh MA, Tanaka WK, Wagner JA, Zhu H. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. J Clin Endocrinol Metab 92: 1754-1757, 2007.
4. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194-206, 2007.
5. Anderson KD, Garcia K, Herman JP, Murphy A, Okamoto H, Shen V, Sleeman MW, Thabet K, Tschop M, Wortley KE, Yancopoulos GD. Peptide YY regulates bone turnover in rodents. Gastroenterology (in press), 2007.
6. 3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 293: E604-E609, 2007.
7. 3-36 on appetite, energy intake, energy expenditure, and glucose and fat metabolism in obese and lean subjects. Am J Physiol Endocrinol Metab 292: E1062-E1068, 2007.
8. Athanacio J, Coffey T, Jodka C, Mack C, Maier H, Parkes D, Roth J, Weyer C. Combination therapy with amylin and PYY3-36 in obese rodents: anorexigenic synergy and weight loss additivity. Endocrinology Aug 30 [e-pub ahead of print], 2007.
9. Aylwin SJ, Batterham RL, Bloom SR, Borg CM, Gardiner J, Ghatei MA, Kent A, Le Roux CW, Patterson M, Vincent RP, Wynne KJ. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147: 3-8, 2006.
10. Babu M, Bansiewicz T, Herzig KH, Makela K, Miettinen P, Purhonen AK, Walkowiak J. Effect of total colectomy and PYY infusion on food intake and body weight in rats. Regul Pept 131: 29-33, 2005.
11. Baggio L, Drucker DJ, Leiter AB, Lindner J, Magnuson MA, Ratineau C, Ray SK, Schonhoff S. Energy homeostasis and gastrointestinal endocrine differentiation do not require the anorectic hormone peptide YY. Mol Cell Biol 25: 4189-4199, 2005.
12. Baker SB, Burnett MS, Fricke ST, Herzog H, Johnson MD, Kitlinska JB, Kuo LE, Kvetnansky R, Lee EW, Li L, Tilan JU, Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13: 803-811, 2007.
13. Baldock P, Boey D, Couzens M, Dallmann R, Enriquez R, Herzog H, Karl T, Lee N, Lin S, Sainsbury A, Slack K. Peptide YY ablation in mice leads to the development of hyperinsulinaemia and obesity. Diabetologia 49: 1360-1370, 2006.
14. Ballantyne GH. Peptide YY(1-36) and peptide YY(3-36). Part II. Changes after gastrointestinal surgery and bariatric surgery. Obes Surg 16: 795-803, 2006.
15. Batterham RL, Bell JD, Chandarana K, Chivers JE, Heffron H, Herzog H, Kapoor S, Le Roux CW, Thomas EL, Withers DJ. Critical role for peptide YY in protein-mediated satiation and body-weight regulation. Cell Metab 4: 223-233, 2006.
16. Batterham RL, Bloom SR, Brynes AE, Cohen MA, Cone RD, Cowley MA, Dakin CL, Ghatei MA, Herzog H, Low MJ, Small CJ, Wren AM. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418: 650-654, 2002.
17. Batterham RL, Bloom SR, Cohen MA, Ellis SM, Frost GS, Ghatei MA, Le Roux CW, Withers DJ. Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349: 941-948, 2003.
18. Beglinger C, Degen L, Drewe J, Graf S, Ketterer S, Oesch S. Effect of peptide YY3-36 on food intake in humans. Gastroenterology 129: 1430-1436, 2005.
19. Benoit SC, Castaneda TR, Cuntz U, D'Alessio DA, Kampe J, Koebnick C, Kruthaupt T, Moehlig M, Otto B, Pfeiffer AF, Pfluger PT, Rochlitz HJ, Spranger J, Tschop M, Vahl T, Weickert MO. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 92: 583-588, 2007.
20. Bessler M, Conwell IM, Daud A, Inabnet W, Korner J, Olivero-Rivera L, Restuccia NL, Taveras C. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels. Obesity (Silver Spring) 14: 1553-1561, 2006.
21. Bloom SR, Chanoine JP, Ghatei MA, Kieffer TJ, Leichner P, Stock S, Wong AC. Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin Endocrinol Metab 90: 2161-2168, 2005.
22. Brodows RG; Study Group GWAA, Heine RJ, Johns D, Mihm MJ, Van Gaal LF, Widel MH. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143: 559-569, 2005.
23. Buckholz TM, DeCarr LB, Fisk SE, Lumb KJ, Mahle CD, Mays MR, Milardo LF, Pellegrino CM, Ortiz AA. Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice. J Med Chem 50: 2264-2268, 2007.
24. Chan JL, Goldfine AB, Mantzoros CS, Mun EC, Stoyneva V. Peptide YY levels are elevated after gastric bypass surgery. Obesity (Silver Spring) 14: 194-198, 2006.
25. Colmers WF, Cone RD, Ghamari-Langroudi M. PYY3-36 inhibits the action potential firing activity of POMC neurons of arcuate nucleus through postsynaptic Y2 receptors. Cell Metab 2: 191-199, 2005].
26. Cone RD, Ellacott KL, Fan W, Halatchev IG. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145:2585-2590, 2004.
27. Cone RD, Halatchev IG. Peripheral administration of PYY(3-36) produces conditioned taste aversion in mice. Cell Metab 1: 159-168, 2005.
28. Hamberger B, Hellstrom PM, Hokfelt T, Lundberg JM, Mutt V, Tatemoto K, Terenius L. Localization of peptide YY (PYY) in gastrointestinal endocrine cells and effects on intestinal blood flow and motility. Proc Natl Acad Sci USA 79: 4471-4475, 1982.